A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses-Reference-Cited by-同舟云学术

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

Published:2008-01-11 Issue:3 Volume:112 Page:533-543
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Cameron David,Casey Michelle,Press Michael,Lindquist Deborah,Pienkowski Tadeusz,Romieu C. Gilles,Chan Stephen,Jagiello-Gruszfeld Agnieszka,Kaufman Bella,Crown John,Chan Arlene,Campone Mario,Viens Patrice,Davidson Neville,Gorbounova Vera,Raats Johannes Isaac,Skarlos Dimosthenis,Newstat Beth,Roychowdhury Debasish,Paoletti Paolo,Oliva Cristina,Rubin Stephen,Stein Steven,Geyer Charles E.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10549-007-9885-0.pdf

Reference19 articles.

1. Stern DF (2000) Tyrosine kinase signaling in breast cancer: ErbB family receptor tyrosine kinases. Breast Cancer Res 2:176–183

2. Slamon DJ, Clark GM, Wong SG et al (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177–182

3. Press MF, Slamon DJ, Flom KJ, Park J, Zhou J-Y, Bernstein L (2002) Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol 20:3095–3105

4. Cobleigh MA, Vogel CL, Tripathy D et al (1999) Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639–2648

5. Vogel CL, Cobleigh MA, Tripathy D et al (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719–726

Cited by 677 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Stereotactic radiosurgery for brain metastases from human epidermal receptor 2 positive breast Cancer: an international, multi-center study;Journal of Neuro-Oncology;2024-08-27

2. PI3K PROTAC overcomes the lapatinib resistance in PIK3CA-mutant HER2 positive breast cancer;Cancer Letters;2024-08

3. Mechanisms of acquired resistance to HER2-Positive breast cancer therapies induced by HER3: A comprehensive review;European Journal of Pharmacology;2024-08

4. Phase Ib and pharmacokinetics study of alpelisib, a PIK3CA inhibitor, and capecitabine in patients with advanced solid tumors;Frontiers in Oncology;2024-07-12

5. Disitamab vedotin, a HER2‐directed antibody‐drug conjugate, in patients with HER2‐overexpression and HER2‐low advanced breast cancer: a phase I/Ib study;Cancer Communications;2024-06-28